Confirmed presentations (as of April 2015)
Animal models for assessing ALS therapy
Robert Brown, USA
The future of Neurotherapeutics: Stroke
Louis Caplan, USA
Informed consent in Alzheimer’s disease and other dementing conditions
Anjan Chatterjee, USA
Animal models for neurological diseases: Stroke
Michael Chopp, USA
The future of Neurotherapeutics: Infections
David Clifford, USA
Autoimmune Diseases of the Synapse: Novel clinical paradigms, models of disease and therapeutic implications
Josep Dalmau, USA
When to use steroids therapy in the various VZV clinical presentations
Donald Gilden, USA
How to differentiate between organic and non-organic symptomatology of movement disorders
Mark Hallett, USA
Length of Multiple Sclerosis pivotal studies (panelist)
David Leppert, Switzerland
Round table discussion on orphan drugs
Paul Matthews, UK
Therapy of NeuroAIDS
Avi Nath, USA
Therapy of Lyme disease and post Lyme Disease Syndrome
Andrew Pachner, USA
Treatment of ataxia
Massimo Pandolfo, Belgium
Viral and non viral vectors in gene therapy
Amos Panet, Israel
Length of Multiple Sclerosis pivotal studies
Nancy Richert, USA
Therapy of orphan neurological diseases (panelist)
John Richert, USA
The perspectives of the new disease-modifying strategies in Alzheimer’s disease
Elio Scarpini, Italy
Animal models for neurological diseases: Multiple sclerosis
Subramaniam Sriram, USA
Promise and obstacles of gene therapy in muscular dystrophies
Thomas Voit, USA
Thymectomy in myasthenia
Gil Wolfe, USA